The utility of mTOR signalling pathway dysregulation and mutational profiling in the risk stratification for future cognitive decline in Mild Cognitive Impairment (MCI).

该项目将评估mTOR信号通路失调和DNA序列分析在轻度认知障碍（MCI）未来认知下降风险分层中的临床效用。mTOR通路的失调已被确定为AD发展的风险因素。该项目将证实专有生物标志物是证明这种失调的有效替代物。MCI可能是AD（阿尔茨海默病）的前驱状态，并且这些患者中的50-60%处于进展为AD的高风险中。目前AD的预后方法在早期MCI中的准确率仅为25-30%。缺乏经过验证的生物标志物阻碍了AD的临床管理和新疗法的产生。该项目将研究一个大型受影响患者队列，以证明一组已确定的高危AD生物标志物的有效性。这样的预后测试是必不可少的，使紧急AD治疗的有意义的临床试验。该项目与英国痴呆症挑战的目标保持一致，首相在最近的八国集团痴呆症峰会上重申了这一目标。

This project will evaluate the clinical utility of mTOR signalling pathway dysregulation and DNA sequence profiling in the risk stratification for future cognitive decline in Mild Cognitive Impairment (MCI). Dysregulation of the mTOR pathway has been identified as a risk factor in the development of AD. This project will confirm that proprietary biomarkers are an effective surrogate of demonstrating this dysregulation. MCI may be a prodromal state for AD (Alzheimer's Disease) and 50-60% of these patients are at high risk of progression to AD. Current prognostic methods for AD are only 25-30% accurate in early MCI. The lack of validated biomarkers hampers clinical management of AD and the production of new therapies. This project will study a large cohort of affected patients to demonstrate the validity of a panel of identified at-risk AD biomarkers. Such a prognostic test is essential to enable meaningful clinical trials of emergent AD therapies. This project aligns well with the aims of the UK Dementia Challenge, re-stated by the Prime Minister at the recent G8 Dementia Summit.